Richard Boyce (Presenter)
University of Pittsburgh
Isabelle Ragueneau-Majlessi, University of Washington
Jingjing Yu, University of Washington
Jessica Sontheimer, University of Washington
Chris Kinsella, University of Washington
Mathias Brochhausen, University of Arkansas for Medical Sciences
John Judkins, University of Arkansas for Medical Sciences
Bruce Pinkleton, Washington State University
Rebecca Cooney, Washington State University
Mary Paine, Washington State University
Jeannine McCune, University of Washington
Abstract: Concomitant use of prescription drug therapies and natural products is a frequent occurrence and raises concerns about safety. The impact on safety of pharmacokinetic-based natural product – drug interactions (PK-NPDIs) is often unknown. A new Center of Excellence for PK-NPDI research has been established and is creating a publicly accessible database where researchers can access scientific results, raw data, and recommended methodology to enable optimal assessment of the clinical significance of PK-NPDIs.
Learning Objective 1: How a new publicly accessible database will help researchers assess the potential impact on safety of pharmacokinetic-based natural product – drug interactions (PK-NPDIs).